Mouse models have markedly improved our understanding of cancer development and tumor biology. However, these models have shown limited efficacy as tractable systems for unbiased genetic experimentation. Here, we report the adaptation of loss-of-function screening to mouse models of cancer. Specifically, we have been able to introduce a library of shRNAs into individual mice using transplantable E-myc lymphoma cells. This approach has allowed us to screen nearly 1,000 genetic alterations in the context of a single tumor-bearing mouse. These experiments have identified a central role for regulators of actin dynamics and cell motility in lymphoma cell homeostasis in vivo. Validation experiments confirmed that these proteins represent bona fide lymphoma drug targets. Additionally, suppression of two of these targets, Rac2 and twinfilin, potentiated the action of the front-line chemotherapeutic vincristine, suggesting a critical relationship between cell motility and tumor relapse in hematopoietic malignancies.
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Genetic screens in the mouse hematopoietic system have proven to be highly effective strategies for identifying novel and cooperating cancer genes. For example, Moloney murine leukemia virus-based insertional mutagenesis screens first characterized the potent oncogenes Bmi1 and Pim1, Pim2 and Pim3 (refs. 1,2). These screens have since been performed on numerous sensitized backgrounds, providing significant insight into the relationship between specific oncogenic and tumor suppressor alterations 3 . The more recent development of mice expressing active transposons has similarly facilitated the identification of previously unrecognized cancer genes [4] [5] [6] . Although these approaches have been highly successful, they have several notable limitations. First, genes affected by insertional mutagenesis are identified as likely candidates based on proximity to the insertion site. Thus, numerous mice are required to identify common insertion sites, and affected genes need to be functionally validated. Second, despite the use of highly recombinant genetic backgrounds, the identification of relevant tumor suppressor genes by insertional mutagenesis is inefficient. Finally, insertional mutagenesis requires positive selection for a given phenotype, generally tumor development. Thus, sensitization screens based on the selective depletion of a given insertion site cannot be performed.
We have recently adapted miRNA-based short hairpin RNA (shRNA) gene silencing to in vivo applications in the Eµ-myc lymphoma mouse, a well-established model of B-cell lymphoma [7] [8] [9] . This approach has subsequently been expanded to examine small sets of shRNAs in a cohort of mice 10 . However, despite the disseminated and effective use of cell-based RNA interference (RNAi) screens [11] [12] [13] [14] [15] [16] [17] , adaptation of these approaches to mouse models has been limited. Here, we use RNAi to interrogate loss-of-function phenotypes for large gene sets in the context of individual mice. Results from this study identify a set of genes involved in cytoskeletal organization and cell migration that are important for lymphoma progression in vivo. Notably, this study demarcates critical determinants of tumor behavior in vivo, information that could not be obtained using conventional cell-based screening approaches.
Previous studies in the Eµ-myc system have suggested that Eµ-myc lymphomas are largely composed of cells with tumorinitiating potential. Specifically, tumor cell dilution experiments have shown that as few as 10 tumor cells can produce tumors following tail-vein injection into syngeneic recipient mice 18 . Thus, we reasoned that if nearly all tumor cells have the capacity to contribute to tumor formation following transplantation, then this system might accommodate the introduction of a diverse set of shRNA-infected cells into a given tumor. To test this, we performed a dilution experiment using lymphoma cell cultures that were partially transduced with a retroviral vector coexpressing an shRNA targeting topoisomerase 2α (Top2A), an essential mediator of the cytotoxic effects of the chemotherapeutic doxorubicin 19 , and the gene encoding green fluorescent protein (GFP) to mark infected cells. Viral multiplicity of infection (MOI) was titered such that either 2.0% or 0.2% of lymphoma cells were infected. These partially transduced lymphoma cell populations were injected into syngeneic recipient mice, and mice were treated with doxorubicin at the time of lymphoma presentation. At both infection efficiencies, we saw a significant increase in the percentage of GFP + cells following treatment ( Fig. 1a) . These results showed that cells representing as little as 1/500th of the injected lymphoma cell population were retained at the time of doxorubicin treatment. These data are consistent with large numbers of lymphoma cells (at least 500) contributing to an individual tumor following transplantation in vivo, and they suggest the E-myc lymphoma model may be appropriate for in vivo, poolbased RNAi screens with complex shRNA libraries. On the basis of these preliminary results, we performed an shRNA screen with a pool of approximately 2,250 hairpins targeting 1,000 genes with known or putative roles in cancer 19 . Retroviral plasmids expressing these shRNAs, as well as GFP, were pooled and packaged as a mixture of retroviruses. This retroviral pool was then used to infect lymphoma cells, and the resulting transduced cells were injected into recipient mice, maintained in culture, or collected immediately to serve as a reference sample ( Fig. 1b) . At the time of lymphoma presentation, tumors were harvested and genomic DNA was extracted from primary tumors and cultured cells. After PCR amplification of shRNAs from genomic DNA using common primers ( Fig. 1b) , hairpin representation was analyzed by high-throughput sequencing.
Approximately 1,600 of the original 2,250 unique hairpins could be identified from each in vitro-cultured sample, and, unexpectedly, between 600 and 900 unique hairpins could be identified in lymphomas from individual mice ( Fig. 1c) . Thus, a large, diverse shRNA set can be introduced in vivo, and a significant proportion of the initial library complexity can be maintained in this setting. Sequencing of shRNAs from genomic DNA derived from outgrown single-cell clones showed that ~90% of cells were infected with only a single shRNA ( Supplementary Fig. 1 ), suggesting that, at a minimum, 900 cells can contribute to the lymphoma burden in an individual mouse. Thus, not only can a large percentage of lymphoma cells give rise to a tumor following transplantation, but, in fact, many of these cells contribute to the growth of the resulting tumor.
Unsupervised hierarchical clustering showed that the three in vivo samples were more similar to one another than to any of the cultured in vitro samples, based on the hairpins that were enriched or depleted in each setting ( Fig. 1d) . Thus, the set of genes that influences cancer cell homeostasis in vitro is distinct from those that are central to tumor growth in vivo. Notably, the number of sequencing reads obtained was Cells were infected with a vector control or a retrovirus coexpressing GFP and an shRNA targeting Top2A (shTop2a). Partially transduced cell populations were injected into recipient mice. Palpable tumors were treated with doxorubicin, and the percentage of GFP + lymphoma cells was assayed at tumor relapse. (b) In vivo RNAi screening strategy. Lymphoma cells were infected with a pool of retroviruses containing 2,250 distinct hairpins, and transduced lymphoma cell populations were injected into three recipient mice or passaged in three separate culture dishes. Lymphomas were harvested from tumor-bearing mice, and shRNAs were PCR amplified from genomic DNA derived from tumors or from cultured cells. sufficient to see both enrichment and depletion of shRNAs from the initial injected population. Although many shRNAs showed similar changes in representation in clustered samples, significant variation was also present in samples of the same type. This is likely to be due to the stochastic gain or loss of shRNAs following introduction into mice or serial replating in culture.
Hairpins whose representation was decreased at least tenfold in all three replicates or was enriched at least fivefold in two out of three replicates, relative to their representation in the control cell population collected shortly after retroviral transduction, scored as candidate hits. The set of scoring shRNAs in vitro determined by this criterion was largely nonoverlapping with the set of shRNAs that scored in vivo (Fig. 1e, Supplementary Table 1) , indicating that by performing shRNA screens in the context of a normal tumor microenvironment, we were able to identify a set of genes that exclusively affects growth in a physiologically relevant setting.
We focused our follow-up studies on shRNA sets that specifically affected tumor growth in vivo. As a more stringent criterion, we selected genes for which two or more cognate shRNAs were depleted on average at least tenfold in mice ( Table 1) . As determined based on gene ontology (GO) classifications and manual curation, shRNAs targeting genes involved in cell motility, including dynamic actin reorganization and cell adhesion, were highly represented in the set of hairpins that were specifically depleted in vivo (8 of 11). Several of these genes were chosen for validation ( Supplementary  Fig. 2a ). These included genes encoding Rac2, a hematopoieticspecific Rho GTPase important for the formation of lamellipodia during cell migration 20, 21 ; CrkL, an adaptor protein reported to be involved in the activation of Rac 22 ; and Twinfilin (Twf1), an actin monomer-binding and actin filament-capping protein 23 . For these genes, multiple independent shRNAs ( Fig. 2a ) recapitulated the initial screening phenotype. Specifically, although cells grown in the presence of these shRNAs grew robustly in culture, they all showed a selective depletion in lymph nodes after tail-vein injection (Fig. 2b) . To further characterize the efficiency of our screen, we examined a non-motility gene targeted by two depleted shRNAs and two genes targeted by a single scoring shRNA. shRNAs targeting the genes encoding IL-6 (two depleted shRNAs in our screen) and Lyn kinase (one depleted shRNA in our screen) were depleted following their introduction in mice, whereas shRNAs targeting the gene encoding AIF-1 (one depleted shRNA in our screen) were not ( Supplementary  Fig. 2b and data not shown). Thus, shRNAs targeting four out of four genes from the gene set identified using our most stringent criteria validated as single constructs, whereas the validation rate for single scoring shRNAs was lower.
To further characterize the roles of genes identified in our screen in lymphoma homeostasis, we subjected shRNA-infected cells to secondary functional assays. Lymphoma cells suppressing Rac2, CrkL or Twf1 showed motility defects in Transwell migration assays, consistent with a role for these proteins in lymphoma cell migration (Fig. 2c,d and Supplementary Fig. 3a,b) . Additionally, Rac2-deficient lymphoma cells showed defects in SDF-1α-induced migration on fibronectin (Supplementary Videos 1 and 2) . Suppression of Rac2 also resulted in impaired lymphoma cell migration in short-term in vivo engraftment assays. Specifically, lymphoma cells suppressing Rac2 were depleted in the spleen and bone marrow 2 and 24 h after tail-vein injection (Fig. 3a) . In a pattern similar to that resulting from Rac2 knockdown, lymphoma cells suppressing Wave2, an important mediator of cell migration known to function downstream of other Rac proteins 24 , showed chemotaxis defects in vitro and were selectively depleted in the lymph nodes at the time of disease presentation ( Fig. 3b and Supplementary Fig. 3c,d) .
Suppression of Rac2 was also selected against in common sites of lymphoid metastasis, such as the liver, as seen by histology and by GFP enrichment analysis (Figs. 3c,d) . suggesting that Rac2 might represent a meaningful lymphoma drug target. In fact, suppression of Rac2 in lymphoma cells extended both tumor-free and overall survival following tail-vein injection (Fig. 3e,f) . Similarly, lymphomabearing mice treated with NSC23766 (ref. 25) , an inhibitor of Rac1 and Rac2 (Supplementary Fig. 4a) 26 , survived significantly longer than untreated controls (Fig. 4a) . Notably, suppression of Twf1 also delayed tumor progression after tail-vein lymphoma injection (Supplementary Fig. 4b) . Thus, multiple proteins involved in actin reorganization and cell motility represent potential drug targets in B-cell malignancies. Additionally, combinations of shRNAs produced synergistic effects on lymphoma growth (Supplementary Fig. 4c) . Notably, when lymphomas were treated with the chemotherapeutic vincristine, knockdown of Rac2 or Twf1 extended animal survival following drug treatment ( Fig. 4b and Supplementary Fig. 4d) . Importantly, this effect was specific for therapeutic response in vivo, as suppression of Rac2 did not sensitize lymphoma cells to vincristine treatment in culture (data not shown). These results suggest that there is a requirement for tumor cell mobilization in lymphoma relapse and that Rac2 and Twf1 activity is important in this mobilization (Fig. 4c) . It further suggests that Rac2 or Twf1 inhibition, or inhibition of lymphoma cell motility by another mechanism, may synergize with conventional chemotherapeutics in the treatment of lymphoma.
Using a well-established mouse model of B-cell lymphoma, we have adapted RNAi screens to in vivo applications. With this system, we were able to screen over 900 unique hairpins in individual mice. Although improvements in RNAi technology will be required to perform saturating loss-of-function studies, this work demonstrates the feasibility of using large, unbiased shRNA sets for in vivo screens. Notably, unlike conventional microarray studies, this approach investigates gene function, rather than gene expression, and therefore implicates genes as directly relevant to interrogated phenotypes. We can envision using a similar approach to examine modulators of therapeutic response or tissue-specific tumor dissemination. Importantly, identification of similarly tractable genetic systems may permit the adaptation of this screening methodology to study tissue development or the biology of solid tumors. Our screen identified modulators of lymphoma cell motility and chemotaxis as key determinants of tumor homeostasis. This group included known regulators of actin-based cell motility as well as proteins, such as Twf1, with known roles in actin dynamics but no established role in mammalian cell migration. Suppression of Rac2 and Twf1 in lymphoma cells impaired lymphoma cell migration to the lymph nodes and other organs that represent common sites of lymphoid metastasis. Additionally, pharmacological inhibition of Rac2 synergized with a conventional chemotherapeutic to extend the lifespan of tumor-bearing mice. These results highlight a potential therapeutic strategy in hematopoietic cancers, suggesting that, in instances where there is minimal metastasis at the time of initial treatment with traditional chemotherapeutics, suppression of cell migration may improve therapeutic outcome.
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